Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Pengfei Song

Showing results (351-360 of 372) with videos related to

Pageof 38
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2015
FDA Approval: BlinatumomabDonna Przepiorka, Chia-Wen Ko, Albert Deisseroth, et al.
Journal of Clinical Pharmacology|January 11, 2012
Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulationPing Zhao, Manuela de L T Vieira, Joseph A Grillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2020
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2013
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancerGideon M Blumenthal, Nancy S Scher, Patricia Cortazar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast CancerPreeti Narayan, Christy L Osgood, Harpreet Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2020
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast CancerSakar Wahby, Lola Fashoyin-Aje, Christy L Osgood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast CancerMirat Shah, Suparna Wedam, Joyce Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell CarcinomaHarpreet Singh, Michael Brave, Julia A Beaver, et al.
International Journal of Cancer|December 7, 2013
Multilayered molecular profiling supported the monoclonal origin of metastatic renal cell carcinomaYi Huang, Shengjie Gao, Song Wu, et al.
Science Advances|June 17, 2026
Noninvasive whole-brain imaging of glymphatic dynamicsNanchao Wang, Xinyuan Yu, Matthew Lowerison, et al.
Pageof 38

Showing results (351-360 of 372) with videos related to

Sort By:
Pageof 38
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 17, 2015
FDA Approval: BlinatumomabDonna Przepiorka, Chia-Wen Ko, Albert Deisseroth, et al.
Journal of Clinical Pharmacology|January 11, 2012
Evaluation of exposure change of nonrenally eliminated drugs in patients with chronic kidney disease using physiologically based pharmacokinetic modeling and simulationPing Zhao, Manuela de L T Vieira, Joseph A Grillo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 23, 2020
FDA Approval Summary: Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial CarcinomaElaine Chang, Chana Weinstock, Lijun Zhang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 27, 2013
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancerGideon M Blumenthal, Nancy S Scher, Patricia Cortazar, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 23, 2021
FDA Approval Summary: Fam-Trastuzumab Deruxtecan-Nxki for the Treatment of Unresectable or Metastatic HER2-Positive Breast CancerPreeti Narayan, Christy L Osgood, Harpreet Singh, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2020
FDA Approval Summary: Accelerated Approval of Sacituzumab Govitecan-hziy for Third-line Treatment of Metastatic Triple-negative Breast CancerSakar Wahby, Lola Fashoyin-Aje, Christy L Osgood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 15, 2020
FDA Approval Summary: Tucatinib for the Treatment of Patients with Advanced or Metastatic HER2-positive Breast CancerMirat Shah, Suparna Wedam, Joyce Cheng, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 1, 2016
U.S. Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell CarcinomaHarpreet Singh, Michael Brave, Julia A Beaver, et al.
International Journal of Cancer|December 7, 2013
Multilayered molecular profiling supported the monoclonal origin of metastatic renal cell carcinomaYi Huang, Shengjie Gao, Song Wu, et al.
Science Advances|June 17, 2026
Noninvasive whole-brain imaging of glymphatic dynamicsNanchao Wang, Xinyuan Yu, Matthew Lowerison, et al.
Pageof 38